NCT05293236 is a Phase 1 clinical trial of ApTOLL in COVID-19, sponsored by Macarena Hernández Jiménez.

Who is sponsoring NCT05293236?

NCT05293236 is sponsored by Macarena Hernández Jiménez.

What drugs are being tested in NCT05293236?

Interventions in NCT05293236: ApTOLL, Saline.

Is NCT05293236 still recruiting?

NCT05293236 is currently terminated. Last updated 7 August 2023.

Last reviewed 2023-08-07 · How we verify

NCT05293236

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ApTOLL for the Treatment of COVID-19

Terminated Phase 1 Last updated 7 August 2023

What this trial tests

Phase 1 trial testing ApTOLL in COVID-19 in 5 participants. Terminated before completion.

Timeline

14 January 2022

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Macarena Hernández Jiménez
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	triple
Primary purpose	treatment
Enrollment	5
Start date	14 January 2022
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	4 locations across Spain

Drugs / interventions tested

ApTOLL — full drug profile →
Saline

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Macarena Hernández Jiménez

Who can join

Adults 18 to 85, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is a clear and urgent medical need of developing new medicinal products for COVID-19 since there are poor pharmacological tools to block the progression of patients to cytokine storm syndrome (CSS). To this aim, this Phase Ib clinical study (APTACOVID) pretends to determine whether ApTOLL, in combination with the standard of care, is safe and shows any biological effect) in those patients infected with SARS-CoV-2 who are not developed CSS yet.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.
Liu M, Wang Y, Zhang Y, Hu D, et al · · 2025 · cited 62× · PMID 40059188 · DOI 10.1038/s41392-024-02112-8
Pattern recognition receptors: function, regulation and therapeutic potential.
Chen R, Zou J, Chen J, Zhong X, et al · · 2025 · cited 53× · PMID 40640149 · DOI 10.1038/s41392-025-02264-1
Aptamers targeting SARS-COV-2: a promising tool to fight against COVID-19.
Zhang Y, Juhas M, Kwok CK. · · 2023 · cited 53× · PMID 35995601 · DOI 10.1016/j.tibtech.2022.07.012
Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms.
Brown B, Ojha V, Fricke I, Al-Sheboul SA, et al · · 2023 · cited 32× · PMID 36851285 · DOI 10.3390/vaccines11020408
Contribution of T- and B-cell intrinsic toll-like receptors to the adaptive immune response in viral infectious diseases.
Zhang E, Ma Z, Lu M. · · 2022 · cited 18× · PMID 36224474 · DOI 10.1007/s00018-022-04582-x
Harnessing aptamers against COVID-19: A therapeutic strategy.
Mahmoudi A, Alavizadeh SH, Hosseini SA, Meidany P, et al · · 2023 · cited 15× · PMID 37315763 · DOI 10.1016/j.drudis.2023.103663
Aptamers as Theragnostic Tools in Prostate Cancer.
Cruz-Hernández CD, Rodríguez-Martínez G, Cortés-Ramírez SA, Morales-Pacheco M, et al · · 2022 · cited 13× · PMID 36008950 · DOI 10.3390/biom12081056
Inhaled aptamer therapy: A hopeful therapy for lung disease.
Martin ME. · · 2023 · cited 3× · PMID 37273784 · DOI 10.1016/j.omtn.2023.05.009

Verify or expand the search:

Other trials of ApTOLL

Trials testing the same drug.

NCT05569720 — First in Human Study to Compare Safety Between Intravenous Bolus Versus Infusion of ApTOLL · Phase 1 · completed
NCT04734548 — Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke · Phase 1, PHASE2 · completed
NCT04742062 — First in Human Clinical Trial of ApTOLL in Healthy Volunteers · Phase 1 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05293236 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Macarena Hernández Jiménez
Last refreshed: 7 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05293236.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing